Joshua L. Smiley Acquires 185 Shares of Eli Lilly And Co (NYSE:LLY) Stock

Share on StockTwits

Eli Lilly And Co (NYSE:LLY) CFO Joshua L. Smiley bought 185 shares of the business’s stock in a transaction on Monday, July 15th. The stock was bought at an average price of $108.47 per share, with a total value of $20,066.95. Following the purchase, the chief financial officer now owns 30,595 shares in the company, valued at $3,318,639.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of LLY opened at $108.82 on Wednesday. The company has a market cap of $105.05 billion, a P/E ratio of 19.61, a PEG ratio of 1.92 and a beta of 0.20. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. The firm’s 50-day simple moving average is $113.73. Eli Lilly And Co has a 12-month low of $88.17 and a 12-month high of $132.13.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. The company had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. Eli Lilly And Co’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $1.31 EPS. On average, equities research analysts expect that Eli Lilly And Co will post 5.67 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $0.645 per share. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.37%. Eli Lilly And Co’s dividend payout ratio is 46.49%.

LLY has been the subject of several analyst reports. TheStreet downgraded Trade Desk from a “b-” rating to a “c-” rating in a research note on Thursday, May 9th. ValuEngine downgraded WideOpenWest from a “hold” rating to a “sell” rating in a research report on Friday, June 28th. BMO Capital Markets reiterated a “hold” rating and set a $45.00 price target on shares of SAP in a research report on Wednesday, May 1st. Goldman Sachs Group set a $27.00 price target on Melco Resorts & Entertainment and gave the company a “buy” rating in a research report on Tuesday, May 28th. Finally, Guggenheim lifted their price target on Intuit from $260.00 to $310.00 in a research report on Thursday, April 11th. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $121.10.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wakefield Asset Management LLLP purchased a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $27,000. Trust Department MB Financial Bank N A raised its holdings in shares of Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after buying an additional 82 shares in the last quarter. Meridian Wealth Management LLC purchased a new position in shares of Eli Lilly And Co during the 1st quarter valued at about $38,000. WP Advisors LLC purchased a new position in shares of Eli Lilly And Co during the 1st quarter valued at about $38,000. Finally, Clarfeld Financial Advisors LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $52,000. 79.39% of the stock is currently owned by institutional investors.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Penny Stocks, Risk and Reward Factors

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report